Clinical trial
AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00305656 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00305656 |
|---|---|
| Title | AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme |
| Official title | A Phase II Study of AZD2171 in Recurrent Glioblastoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor |
| Intervention type | Drug |
| Interventions | cediranib maleate |
| Enrollment | 31 |
| Start date | Jan 1, 2006 |
| Primary completion | Apr 1, 2012 |
| First posted | Mar 22, 2006 |
| Last update posted | Aug 22, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: